Nexentis Technologies (STU:80W0) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:80W0 Nexentis Technologies Inc STU:80W0
44 GF Score
Price €890.09
GF Value €1,600.26
! 2 Warning Signs
View Full Analysis

What is Nexentis Technologies Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:80W0
44GF Score
Nexentis Technologies Inc STU:80W0
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nexentis Technologies (STU:80W0) Overvalued in 2026?

Based on GuruFocus' analysis, Nexentis Technologies stock appears to be undervalued. The current stock price of €890.09 is trading 44.4% below its estimated GF Value™ of €1,600.26.

Key valuation signals for STU:80W0:

  • Dividends Received:
  • GF Value™: €1,600.26 vs. price of €890.09 (44.4% below fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the STU:80W0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nexentis Technologies Business Description

Other Exchanges NXTS:USA
Address Pinhas Sapir Street 3, Kiryat HaMada, Ness Ziona, ISR, 7403626
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.
44GF Score

Get the complete analysis for STU:80W0

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€890.09
Price
€1,600.26
GF Value